These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38916702)

  • 21. Measurement of pH, electrolytes and electrophoretic studies of tear proteins in tears of patients with dacryoliths: a novel concept for dacryoliths.
    Lew H; Lee SY; Yun YS
    Ophthalmologica; 2004; 218(2):130-5. PubMed ID: 15004503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO).
    Ali MJ
    Prog Retin Eye Res; 2023 Sep; 96():101193. PubMed ID: 37394093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher incidence of meibomian gland dysfunction in postmenopausal women with primary acquired nasolacrimal duct obstruction.
    Wang G; Jin H; Sheng Y; Ji F; Liu Y; Han L; Wang X; Chen X; Ding H; Liu J; Fu Q
    Int Ophthalmol; 2024 Feb; 44(1):70. PubMed ID: 38349418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of dye disappearance test and tear meniscus height in diagnosis and postoperative assessment of nasolacrimal duct obstruction.
    Roh JH; Chi MJ
    Acta Ophthalmol; 2010 May; 88(3):e73-7. PubMed ID: 20546233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and Risk Factors of Dry Eye Symptoms after Successful Dacryocystorhinostomy for Patients with Lacrimal Passage Obstruction.
    Jin Y; Guo Y; Liu Y; Wang Y; Qin G; Tian Y; Li X
    Eur J Ophthalmol; 2022 Sep; 32(5):2662-2669. PubMed ID: 34931533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tear protein analysis in patients with primary acquired nasolacrimal duct obstruction treated with lacrimal passage intubation.
    Yaginuma S; Konno K; Shigeyasu C; Yamada M
    Jpn J Ophthalmol; 2021 May; 65(3):409-415. PubMed ID: 33411097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anatomic characteristics of primary acquired nasolacrimal duct obstruction: a comparative computed tomography study.
    Wang W; Gong L; Wang Y
    Quant Imaging Med Surg; 2022 Nov; 12(11):5068-5079. PubMed ID: 36330196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of primary acquired nasolacrimal duct obstruction.
    Kashkouli MB; Sadeghipour A; Kaghazkanani R; Bayat A; Pakdel F; Aghai GH
    Orbit; 2010 Feb; 29(1):11-5. PubMed ID: 20302403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcanalicular endoscopic dacryoplasty in patients with primary acquired nasolacrimal duct obstruction.
    Lee SM; Lew H
    Graefes Arch Clin Exp Ophthalmol; 2021 Jan; 259(1):173-180. PubMed ID: 32743774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nasolacrimal canal morphology with or without idiopathic obstruction in Caucasian adults: a multidetector CT study.
    Ulutas HG; Yazici B; Ulutas E; Yazici Z
    Int Ophthalmol; 2022 Jun; 42(6):1727-1735. PubMed ID: 35079938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing clinical outcomes for endoscopic lacrimal duct recanalization in patients with complete PANDO.
    Javate RM
    Int Ophthalmol; 2023 Jan; 43(1):175-184. PubMed ID: 35809164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction.
    Seider N; Miller B; Beiran I
    Am J Ophthalmol; 2008 Jan; 145(1):120-123. PubMed ID: 17915187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are inflammation-related diseases risk factors for primary acquired nasolacrimal duct obstruction? A large scale, national case-control study.
    Kerber L; Kerman T; Hazan I; Ziv O; Kordelul S; Tsumi E
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; 262(6):1911-1917. PubMed ID: 38194111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular surface predisposing factors for digital display-induced dry eye.
    Talens-Estarelles C; García-Marqués JV; Cerviño A; García-Lázaro S
    Clin Exp Optom; 2023 May; 106(4):373-379. PubMed ID: 35254958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemiology of dry eye disease in the UK: The Aston dry eye study.
    Vidal-Rohr M; Craig JP; Davies LN; Wolffsohn JS
    Cont Lens Anterior Eye; 2023 Jun; 46(3):101837. PubMed ID: 37003925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reliability of fluorescein dye disappearance test in assessment of adults with nasolacrimal duct obstruction.
    Kashkouli MB; Mirzajani H; Jamshidian-Tehrani M; Pakdel F; Nojomi M; Aghaei GH
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):167-9. PubMed ID: 23503058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment.
    Yartsev VD; Atkova EL; Ekaterinchev MA
    Int Ophthalmol; 2023 Sep; 43(9):3385-3390. PubMed ID: 37199817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of long-term glycaemic control on tear break-up times and dry eye symptoms in Chinese patients with type 2 diabetes.
    Ma A; Mak MS; Shih KC; Tsui CK; Cheung RK; Lee SH; Leung H; Leung JN; Leung JT; Van-Boswell MZ; Wong MT; Ng AL; Lee CH; Jhanji V; Tong L
    Clin Exp Ophthalmol; 2018 Aug; 46(6):608-615. PubMed ID: 29345402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Location and pattern of non-invasive keratographic tear film break-up according to dry eye disease subtypes.
    Kim J; Kim JY; Seo KY; Kim TI; Chin HS; Jung JW
    Acta Ophthalmol; 2019 Dec; 97(8):e1089-e1097. PubMed ID: 31062499
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.